Richard Gonzalez, AbbVie CEO (Chris Kleponis via AP Images)
December 19, 2022 01:33 PM ESTUpdated 03:30 PM
Pharma
FDA+

Ab­b­Vie adds de­pres­sion in­di­ca­tion to Vray­lar's la­bel months af­ter Gon­za­lez touts $4B+ peak sales po­ten­tial

Nicole DeFeudis

Editor

Ab­b­Vie CEO Richard Gon­za­lez wants to bring Vray­lar to new heights. On Fri­day, reg­u­la­tors set the next phase of his plan in mo­tion.

The FDA …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Pfiz­er wants in on Sum­mit’s goal to beat Keytru­da via ADC com­bos

Post-Hoc: Phar­ma CEOs' al­ter­na­tive re­al­i­ty with Trump

Sanofi, Te­va bol­ster case for IBD drug with Phase 2 da­ta, de­spite po­ten­tial com­pe­ti­tion

Pfiz­er hires ex-FDA deputy Pa­trizia Cavaz­zoni as chief med­ical of­fi­cer

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times